UPC_APP_68658/2024

METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY

Procedural & sub-applicationsDocument Access (RoP262)Milan CDGenericCase Closed

2025-02-03DismissedproceduralApplication RoP262.1 (b)
Application by STADAPHARM GmbH for public access to case documents under R.262.1(b) RoP (separate application number for the same underlying proceedings UPC_CFI_698/2024, Milan Central Division). Outcome identical to companion order: STADAPHARM's request to access documents was dismissed; NOVARTIS's request for legal cost compensation was dismissed. This appears to be the same decision issued under a different application reference number.